| 000 | 01734 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515045454.0 | ||
| 264 | 0 | _c20061226 | |
| 008 | 200612s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/01.wnl.0000242629.66372.33 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPhillips, J T | |
| 245 | 0 | 0 |
_aInfusion-related hypersensitivity reactions during natalizumab treatment. _h[electronic resource] |
| 260 |
_bNeurology _cNov 2006 |
||
| 300 |
_a1717-8 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aCatecholamines _xtherapeutic use |
| 650 | 0 | 4 |
_aDrug Hypersensitivity _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHistamine H1 Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfusions, Intravenous _xadverse effects |
| 650 | 0 | 4 |
_aMonitoring, Physiologic _xstandards |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aNatalizumab |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aO'Connor, P W | |
| 700 | 1 | _aHavrdova, E | |
| 700 | 1 | _aHutchinson, M | |
| 700 | 1 | _aKappos, L | |
| 700 | 1 | _aMiller, D H | |
| 700 | 1 | _aPolman, C H | |
| 700 | 1 | _aLublin, F D | |
| 700 | 1 | _aGiovannoni, G | |
| 700 | 1 | _aWajgt, A | |
| 700 | 1 | _aLynn, F | |
| 700 | 1 | _aPanzara, M A | |
| 700 | 1 | _aSandrock, A W | |
| 773 | 0 |
_tNeurology _gvol. 67 _gno. 9 _gp. 1717-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/01.wnl.0000242629.66372.33 _zAvailable from publisher's website |
| 999 |
_c16674326 _d16674326 |
||